Quarterly ResultMay 11, 2026, 07:56 AM
Intellia Therapeutics Q1 Net Loss $(96.2M), EPS $(0.81); Lonvo-z Phase 3 Positive
AI Summary
Intellia Therapeutics reported a net loss of $(96.2) million, or $(0.81) per share, for Q1 2026, an improvement from $(114.3) million, or $(1.10) per share, in Q1 2025. Collaboration revenue decreased slightly to $15.0 million. The company announced positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in hereditary angioedema (HAE) in April 2026, with preparations underway for a commercial launch in the first half of 2027. Additionally, Intellia entered into a new 12-year lease agreement for office and laboratory space in Cambridge, MA, and is involved in several legal proceedings.
Key Highlights
- Q1 2026 net loss was $(96.2) million, an improvement from $(114.3) million YoY.
- Q1 2026 net loss per share was $(0.81), compared to $(1.10) in Q1 2025.
- Collaboration revenue for Q1 2026 decreased to $15.0 million from $16.6 million YoY.
- Research and development expenses decreased to $80.7 million from $108.4 million YoY.
- Net cash used in operating activities was $(117.3) million for Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $375.9 million as of March 31, 2026.
- Reported positive topline data for lonvo-z in HAE Phase 3 clinical trial in April 2026.
- Planned commercial launch of lonvo-z in the first half of 2027.
Price Impact
More from NTLA